---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009670"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:28:29.436305+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22

## Summary
- Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.
- Cash, equivalents & investments $301.2M at March 31, 2022 vs $319.7M at December 31, 2021.
- Topline ACT-AD Phase 2 data in mild-to-moderate Alzheimer's expected by end of Q2 2022.
- LIFT-AD Phase 3 enrollment target increased to ~420 patients; completion expected in Q3 2022.
- Dosed first patient in SHAPE Phase 2 trial for Parkinson's disease dementia and Dementia with Lewy bodies.

## SEC filing metadata
- accession: 0000950170-22-009670
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/0000950170-22-009670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/atha-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009670
- JSON: https://secwatch.observer/filing/0000950170-22-009670.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.